慢性肾脏病的发病机制及干预新策略

doi:10.6040/j.issn.1671-7554.0.2026.1066

摘要/Abstract

摘要： 慢性肾脏病是严重威胁人类生命与健康的全球性公共卫生问题。其发病机制尚不明确,临床治疗存在药物有限、预后效果不佳,以及针对肾脏纤维化的传统靶点设计和药物研发临床试验效果不理想等问题。本文聚焦肾脏损伤与修复这一关键科学问题,以肾脏组织微环境稳态调控为主线,系统总结研究团队近年在该领域取得的研究进展,重点阐述肾脏损伤过程中,代谢微环境和免疫微环境重塑的病理基础及调控机制,解析肾脏损伤修复的关键细胞群体和分子信号网络,并进一步总结具有临床转化潜力的新型治疗靶点以及促进组织修复和肾脏再生的新策略与新技术,以期为肾脏疾病精准诊疗及再生医学策略的开发提供新的理论依据和研究方向。

关键词: 慢性肾脏病, 免疫与代谢, 表观遗传调控, 药物靶点发现, 嵌合抗原受体T细胞

Abstract: Chronic kidney disease(CKD)poses a severe global public health burden, yet its pathogenesis remains incompletely understood and current therapies are limited, with poor prognosis. In particular, conventional anti-fibrotic strategies have shown limited success in clinical translation. Growing evidence suggests that disruption of the renal tissue microenvironment represents a central driver of kidney injury and disease progression. In this article, we highlight the emerging concept that restoration of microenvironmental homeostasis is fundamental to successful renal repair, delineate the cellular and molecular networks that coordinate injury responses, identify key therapeutic targets governing kidney regeneration and fibrosis, and discuss innovative strategies to promote adaptive repair while limiting chronic tissue remodeling. These advances redefine current concepts of CKD pathogenesis and provide a mechanistic foundation for the development of next-generation precision therapies aimed at restoring renal homeostasis and regenerative capacity.

Key words: Chronic kidney disease, Immunometabolism, Epigenetic regulation, Drug target discovery, Chimeric antigen receptor T cells

中图分类号:

R692

王晓杰,张艳,唐伟,谢玉生,王姿颖,孙玉,刘敏,易凡. 慢性肾脏病的发病机制及干预新策略[J]. 山东大学学报 (医学版), 2026, 64(10): 54-59.

WANG Xiaojie, ZHANG Yan, TANG Wei, XIE Yusheng, WANG Ziying, SUN Yu, LIU Min, YI Fan. Pathogenesis and new intervention strategies of chronic kidney disease[J]. Journal of Shandong University (Health Sciences), 2026, 64(10): 54-59.

参考文献

[1] Herrington W G, Judge P K, Grams M E, et al. Chronic kidney disease[J]. Lancet, 2026, 407(10523): 90-104.
[2] 吴飞, 李清丽, 肖振卫. 孟德尔随机化探究细胞因子与慢性肾脏病的因果关系[J]. 山东大学学报(医学版), 2024, 62(11): 85-95. Wu Fei, Li Qingli, Xiao Zhenwei. Causal association between cytokines and chronic kidney disease based on Mendelian randomization[J]. Journal of Shandong University(Health Science), 2024, 62(11): 85-95.
[3] Neuen B L, Fletcher R A, Anker S D, et al. SGLT2 inhibitors and kidney outcomes by glomerular filtration rate and albuminuria: a meta-analysis[J]. JAMA, 2026, 335(3): 233-244.
[4] 尹丹丹, 彦名南, 韩净净, 等. 大黄素治疗糖尿病肾病的网络药理学[J]. 山东大学学报(医学版), 2026, 64(7): 11-27. Yin Dandan, Yan Mingnan, Han Jingjing, et al. Network pharmacology of emodin in the treatment of diabetic kidney disease[J]. Journal of Shandong University(Health Science), 2026, 64(7): 11-27.
[5] Fu Y, Sun Y, Wang M, et al. Elevation of JAML promotes diabetic kidney disease by modulating podocyte lipid metabolism[J]. Cell Metab, 2020, 32(6): 1052-1062.
[6] Bertram J F, Cullen-Mc Ewen L A, Andrade-Oliveira V, et al. The intelligent podocyte: sensing and responding to a complex microenvironment[J]. Nat Rev Nephrol, 2025, 21(7): 503-516.
[7] Fornoni A, Merscher S. Lipid metabolism gets in a JAML during kidney disease[J]. Cell Metab, 2020, 32(6): 903-905.
[8] Qian B, Lu R, Mao S, et al. Podocyte SIRPα reduction aggravates lupus nephritis via promoting T cell inflammatory responses[J]. Cell Rep, 2024, 43(5): 114249. DOI:10.1016/j.celrep.2024.114249
[9] Qian B, Mao S, Chen Y, et al. Podocyte-derived exosomes instruct dendritic cell-dependent CD8(+)T cell activation and proliferation in renal inflammation[J]. J Adv Res, 2026: S2090-1232(26)00057-3. DOI: 10.1016/j.jare.2026.01.032
[10] Du P, Fan B, Han H, et al. NOD2 promotes renal injury by exacerbating inflammation and podocyte insulin resis-tance in diabetic nephropathy[J]. Kidney Int, 2013, 84(2): 265-276.
[11] Li Q, Wang Z, Zhang Y, et al. NLRC5 deficiency protects against acute kidney injury in mice by mediating carcinoembryonic antigen-related cell adhesion molecule 1 signaling[J]. Kidney Int, 2018, 94(3): 551-566.
[12] Huang W, Wang B O, Hou Y F, et al. JAML promotes acute kidney injury mainly through a macrophage-dependent mechanism[J]. JCI Insight, 2022, 7(14): e158571. DOI:10.1172/jci.insight.158571
[13] Zhou D, Zhou M, Wang Z Y, et al. PGRN acts as a novel regulator of mitochondrial homeostasis by facilitating mitophagy and mitochondrial biogenesis to prevent podocyte injury in diabetic nephropathy[J]. Cell Death Dis, 2019, 10(7): 524. DOI:10.1038/s41419-019-1754-3
[14] Zhou M, Tang W, Fu Y, et al. Progranulin protects against renal ischemia/reperfusion injury in mice[J]. Kidney Int, 2015, 87(5): 918-929.
[15] Tadagavadi R K, Reeves W B. NODding off in acute kidney injury with progranulin? [J]. Kidney Int, 2015, 87(5): 873-875.
[16] Van Bree B A, Eichner L J. The impactful role of the HDACs in the regulation of gene expression and as targets for disease therapy[J]. Sci Adv, 2026,12(23): 7295. DOI:10.1126/sciadv.aee7295
[17] 张晓璐, 王丽莉, 陈凯明, 等. 组蛋白去乙酰化酶SIRT1经Toll样受体4途径对巨噬细胞凋亡的调控[J]. 山东大学学报(医学版), 2020, 58(12): 8-14. Zhang Xiaolu, Wang Lili, Chen Kaiming, et al. Mechanism of histone deacetylase SIRT1 inhibiting macrophages apoptosis via TLR4 signaling pathway[J]. Journal of Shandong University(Health Sciences), 2020, 58(12): 8-14.
[18] Wu M, Tan J, Zhou W, et al. SIRT5 Ameliorates cardiac fibrosis via PCK2 desuccinylation-mediated metabolic reprogramming in cardiac fibroblasts[J]. Circulation. 2026,154: 243-64. DOI:10.1161/CIRCULATIONAHA.125.077756
[19] 李卉, 姜朝阳, 刘岩, 等. 组蛋白去乙酰化酶SIRT1调控氧化低密度脂蛋白诱导巨噬细胞凋亡的表达[J]. 山东大学学报(医学版), 2022, 60(1): 6-12. Li Hui, Jiang Chaoyang, Liu Yan, et al. Effects and mechanism of histone deacetylase SIRT1 controlled macrophage apoptosis induced by oxidized low density lipoprotein[J]. Journal of Shandong University(Health Science), 2022, 60(1): 6-12.
[20] Wang X, Liu J, Zhen J, et al. Histone deacetylase 4 selectively contributes to podocyte injury in diabetic nephropathy[J]. Kidney Int, 2014, 86(4): 712-725.
[21] Zhang Y, Yang Y, Yang F, et al. HDAC9-mediated epithelial cell cycle arrest in G2/M contributes to kidney fibrosis in male mice[J]. Nat Commun, 2023, 14(1): 3007. DOI:10.1038/s41467-023-38771-4
[22] Liu M, Liang K, Zhen J, et al. Sirt6 deficiency exacerbates podocyte injury and proteinuria through targeting Notch signaling[J]. Nat Commun, 2017, 8(1): 413. DOI:10.1038/s41467-017-00498-4
[23] Guo J, Wang Z, Wu J, et al. Endothelial SIRT6 is vital to prevent hypertension and associated cardiorenal injury through targeting Nkx3.2-GATA5 signaling[J]. Circ Res, 2019, 124(10): 1448-1461.
[24] Fang W, Wang Z, Li Q, et al. Gpr97 exacerbates AKI by mediating sema3A signaling[J]. J Am Soc Nephrol, 2018, 29(5): 1475-1489.
[25] Ping Y Q, Mao C, Xiao P, et al. Structures of the glucocorticoid-bound adhesion receptor GPR97-G(o)complex[J]. Nature, 2021, 589(7843): 620-626.
[26] Chu Q, Li Y, Wu J, et al. Oxysterol sensing through GPR183 triggers endothelial senescence in hypertension[J]. Circ Res, 2024, 135(7): 708-721.
[27] Li Y, Duan Y, Chu Q, et al. G-protein coupled receptor GPR124 protects against podocyte senescence and injury in diabetic kidney disease[J]. Kidney Int, 2025, 107(4): 652-665.
[28] Li L, Tang W, Zhang Y, et al. Targeting tissue-resident memory CD8(+)T cells in the kidney is a potential therapeutic strategy to ameliorate podocyte injury and glomerulosclerosis[J]. Mol Ther, 2022, 30(8): 2746-2759.
[29] Rheault M N, Alpers C E, Barratt J, et al. Sparsentan versus irbesartan in focal segmental glomerulosclerosis[J]. N Engl J Med, 2023, 389(26): 2436-2445.
[30] Groothof D, Gans R O B, Bakker S J L. Sparsentan and kidney protection: improved medullary oxygenation?[J]. Lancet, 2024, 404(10465): 1808. DOI:10.1016/S0140-6736(24)01168-1
[31] Zhao S, Li R, Xia Y, et al. Targeting ECM-producing cells with CAR-T therapy alleviates fibrosis in chronic kidney disease[J]. Cell Stem Cell, 2025, 32(9): 1390-1402.
[32] Liu L, Wang Y. Severing the scar supply line: CAR-T in chronic kidney disease[J]. CellStem Cell, 2025, 32(9): 1309-1310.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed